RESEARCH MONOGRAPH · KDC-MN-239

Risperidone

May 9, 2026 Kodiac biolabs Research Revised May 11, 2026 3 min read

Our opinion on this compound

81/100

The original second-generation antipsychotic and still a workhorse, with a paliperidone story worth knowing

Risperidone was the compound that essentially defined the second generation of antipsychotics in the early nineties, with the combination of D2 antagonism and high-affinity 5-HT2A antagonism that became the prototype for the class. The pharmacology has been studied to death and the receptor profile is well understood. Strong D2 antagonism, very strong 5-HT2A inverse agonism, alpha-1 antagonism, alpha-2 antagonism, H1 antagonism, with relatively modest muscarinic affinity (cleaner than olanzapine or clozapine on that axis).

What makes risperidone genuinely interesting for research is that its principal active metabolite, paliperidone (9-hydroxyrisperidone), is itself an approved antipsychotic in its own right and has a meaningfully different physicochemical profile than the parent. Lower lipophilicity, lower CYP-dependent clearance, longer half-life. So chronic risperidone exposure delivers two pharmacologically active species with overlapping but distinct properties, and the parent-metabolite ratio depends substantially on CYP2D6 phenotype.

That CYP2D6 dependence is worth knowing about. Poor metabolizers accumulate parent compound, extensive metabolizers shift more toward the metabolite. In behavioral pharmacology this can confound exposure-response work unless you control for it, and in clinical pharmacokinetic work risperidone is a useful 2D6 probe.

The prolactin elevation is the characteristic side effect. Risperidone produces more sustained prolactin elevation than most other atypicals because of the tight D2 binding kinetics in the tuberoinfundibular tract. Thats real and its consistent across studies.

For research, risperidone is the reference second-generation antipsychotic comparator. If you do antipsychotic mechanism work and you arent running risperidone alongside as a baseline, your study probably doesn't make sense. The pharmacology is well characterized enough that you can interpret deviations cleanly.

Sourcing is excellent. Reference material widely available, HPLC validation well established, paliperidone reference standard also accessible.

What we like is that risperidone remains a working tool compound despite being unfashionable. Solid pharmacology, decades of validation, predictable exposure-response. Not exciting, just reliable.

Evidence: 90
Mechanism: 85
Reliability: 85
Safety: 70
Sourcing: 90
Value: 80
Signal: 72
Staying power: 78

Plain-language summary Intrigue 65 / 100

Risperidone (Risperdal) is the most prescribed atypical antipsychotic in the world. Janssen brought it to market in 1993 as the prototype of the combined dopamine D2 plus serotonin 5-HT2A blocker design that defined second-generation antipsychotics. Approved for schizophrenia, bipolar mania, and irritability in autism, it is also widely used off-label in dementia behavioral disturbance and various pediatric conditions. At low doses (1 to 2 mg) it acts more like a typical atypical; at higher doses (above 6 mg) the 5-HT2A advantage washes out and it produces extrapyramidal symptoms and prolactin elevation comparable to older haloperidol. Its active leftover is itself sold separately as paliperidone (Invega). Available as a long-acting injection (Risperdal Consta) for adherence support. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Atypical antipsychotic

A benzisoxazole atypical antipsychotic; the most prescribed atypical worldwide and the prototype combined D2 / 5-HT2A antagonist.

Abstract

Risperidone (3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one; CAS 106266-06-2; molecular formula C23H27FN4O2; molecular weight 410.49) is a benzisoxazole atypical antipsychotic developed at Janssen and approved by the FDA in 1993 under the trade name Risperdal. The receptor profile is the prototype combined D2/5-HT2A antagonist: D2 (Ki approximately 4 nM), 5-HT2A (Ki approximately 0.16 nM, ratio approximately 25:1 favoring 5-HT2A), with secondary alpha-1, alpha-2, and H1 antagonism. At doses below 6 mg the 5-HT2A predominates and EPS is minimal; above 6 mg the D2 antagonism produces dose-dependent EPS approaching haloperidol-like profile. The active metabolite 9-hydroxyrisperidone (paliperidone, marketed as Invega) carries similar receptor profile and contributes substantially to steady-state activity. Risperidone is the most prescribed atypical antipsychotic worldwide. Plasma half-life is 3 hours for parent, 24 hours for paliperidone metabolite. Long-acting injectables (Risperdal Consta, Perseris) provide biweekly or monthly administration. Approved for schizophrenia, bipolar mania, autism-associated irritability. Used as the canonical D2/5-HT2A reference atypical.

Mechanism of action

D2 antagonism plus 5-HT2A antagonism (~25:1 5-HT2A/D2 ratio); secondary alpha-1, alpha-2, H1 antagonism. Active metabolite paliperidone (9-hydroxyrisperidone).

Reported research dose ranges

Clinical 0.5 to 8 mg per oral administration daily. Long-acting injectable 25 to 50 mg biweekly. Rodent studies 0.1 to 3 mg/kg/day.

References

Leysen JE, et al. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988.
Mauri MC, et al. Clinical pharmacology of atypical antipsychotics: an update. EXCLI J 2014.
Csernansky JG, et al. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002.

Read the full monograph

The full reference document is available below as a PDF embed and download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-239 Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Risperidone

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs